[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-mastectomy-pain-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-mastectomy-pain-syndrome":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,56,85,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100644988","super-voltage-prf-of-stellate-ganglion-versus-super-voltage-prf-of-t2-t3-sympathetic-ganglia-in-managing-pmps-100644988",false,"NCT07675096","Super-voltage PRF of Stellate Ganglion Versus Super-voltage PRF of T2 T3 Sympathetic Ganglia in Managing PMPS.","Super-voltage Pulsed Radiofrequency of Stellate Ganglion Versus Super-voltage Pulsed Radiofrequency of T2 T3 Sympathetic Ganglia in Managing Postmastectomy Pain Syndrome.","PMPS PRF","Inclusion Criteria:\n\n* Female patients aged 18-60 years.\n* Patient of class II according to the American society of Anesthesiologists (ASA) physical status classification system.\n* History of unilateral mastectomy for breast cancer.\n* Persistent pain \\>3 months postoperatively.\n* VAS score ≥4 despite pharmacological management.\n* Patients with neuropathic pain who has a score ≥4 by (DN4) questionnaire.\n* Patients on more than 1 antineuropathic drug.\n\nExclusion Criteria:\n\n* Coagulopathy or anticoagulant therapy.\n* Local infection at injection site.\n* History of psychiatric illness or cognitive dysfunction.\n* Previous intervention in the same region (e.g., prior stellate ganglion block or thoracic radiofrequency ablation).\n* Allergy to local anesthetics or contrast agents.","FEMALE","18 Years","60 Years",{"count":21,"type":22},75,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of this study is to compare the effectiveness of super-voltage pulsed radiofrequency of stellate ganglion and super-voltage pulsed radiofrequency of T2-T3 sympathetic ganglia in the treatment of postmastectomy pain syndrome.",[28,29],"Post Mastectomy Pain Syndrome","Chronic Pain Following Surgical Procedure for Cancer",[31,32,33,34,35,36,37,38,39,40,41,42],"Analgesics","Opioids","gabapentin","post mastectomy pain syndrome","chronic pain","Radiofrequency","stellate ganglion block","sympathectomy","T2","T3","SV-PRF","super-voltage pulsed radiofrequency","NOT_YET_RECRUITING","2026-06-23",{"date":46,"type":47},"2026-06-30","ACTUAL",{"date":49,"type":22},"2026-07-01",{"date":51,"type":22},"2027-08-30",{"name":53,"class":54},"National Cancer Institute, Egypt","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":62,"minAge":18,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":66,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100429589","phase-3-prevention-of-persistent-pain-with-lidocaine-infusions-in-breast-cancer-surgery-plan-100429589","NCT04874038","Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)","Inclusion Criteria:\n\n1. Age ≥18 years old\n2. Undergoing a unilateral or bilateral lumpectomy or mastectomy, inclusive of all pathologies, including prophylactic surgery (e.g., family history or BRCA gene mutation)\n\nExclusion Criteria:\n\n1. Previous breast surgery within 6 months of index surgery\n2. Undergoing any autologous flap procedure during index surgery\n3. Presence known chronic pain disorder involving surgical site or ipsilateral chest wall, shoulder, or arm during the 3-months prior to index surgery\n4. Documented hypersensitivity or allergy to lidocaine\n5. Surgery not planned to be performed under general anesthesia and\u002For planned use of regional or neuraxial anesthetic techniques before surgery (i.e., epidural, paravertebral, serratus plane block, pectoralis or modified pectoralis block)\n6. History of ventricular tachycardia, ventricular fibrillation, or atrioventricular block without a pacemaker\n7. Known cirrhotic liver disease\n8. Pregnant\n9. Unlikely to comply with follow-up (e.g. no fixed address, language difficulties that would impede valid completion of questionnaires, plans to move out of town)","ALL","100 Years",{"count":65,"type":22},1602,[67],"PHASE3","Phase III, international multicentre, parallel group, blinded, 1:1 randomized controlled trial to determine the effect of an intraoperative intravenous lidocaine infusion on reducing the development of persistent pain 3-months after breast cancer surgery.",[70,71,72,73],"Post-mastectomy Pain Syndrome","Breast Cancer","Pain, Postoperative","Pain, Chronic","RECRUITING","2026-06-17",{"date":77,"type":47},"2026-06-22",{"date":79,"type":47},"2021-09-22",{"date":81,"type":22},"2026-11-01",{"name":83,"class":54},"University Health Network, Toronto",17,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100560730","regenerative-peripheral-nerve-interface-for-prophylaxis-against-post-breast-surgery-pain-syndrome-100560730","NCT06580951","Regenerative Peripheral Nerve Interface for Prophylaxis Against Post-Breast Surgery Pain Syndrome","Regenerative Peripheral Nerve Interface for Prophylaxis Against Post-Breast Surgery Pain","Inclusion Criteria:\n\n1. Adult female 18 to 65 years of age.\n2. Undergoing breast mastectomy with immediate reconstruction.\n3. Able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. History of chronic pain syndrome unrelated to breast surgery.\n2. Unwillingness or inability to comply with the study's follow-up requirements.\n3. Cognitive impairment or language barriers preventing proper understanding of study procedures and assessments.\n4. Participation in other interventional trials or treatments aimed at pain management that could confound study outcomes as determined by the PI.\n5. Other medical or surgical contraindication to the involved procedure (RPNI) as determined by the PI.","65 Years",{"count":94,"type":22},200,[25],"Regenerative peripheral nerve interface (RPNI) was first developed in 2012 by Dr. Paul Cederna at the University of Michigan as a means for amputees to control their prothesis with their minds. In the decade that followed, it was found RPNI surgery not only provided amputees with neuroma (a growth made up nerve tissue) pain relief but could help prevent neuroma from developing as well.\n\nThis single center, randomized controlled, investigator-initiated study will look at whether the RPNI, a nerve burying procedure involving protecting sensory nerves with a small piece of the patient's pectoralis muscle, performed at the time of the standard mastectomy with immediate breast reconstruction surgery can prevent and\u002For reduce the risk for long-term nerve pain after breast cancer surgery (also called neuroma-related post-breast surgery pain syndrome (PBSPS)) versus the standard surgery alone (Control group). Symptoms of PBSPS include discomfort, numbness, tingling, and shooting pain in the chest and breast area. It is relatively common and may have many causes.\n\nAbout 200 adult females (18-65 years old) who are scheduled to undergo mastectomy with immediate breast reconstruction surgery will be approached for this study. Those who agree and sign the informed consent form will be randomized in 1:1 fashion (50\u002F50 chance) to either the RPNI group or the no RPNI (Control) group. Study participants will complete self-reported surveys (pre-surgery and at Months 1, 3, 6, and 12 post-surgery) designed to measure pain levels, quality of life, and function before and after surgery. Study participation will last approximately 12 months. Subjects will remain blinded to their assigned study arm until their study participation has concluded.",[70],"2026-03-25",{"date":100,"type":47},"2026-03-30",{"date":102,"type":22},"2026-07",{"date":104,"type":22},"2030-07",{"name":106,"class":54},"George Kokosis",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100626648","adding-magnesium-sulphate-to-combined-pectointercostal-plane-and-erector-spinae-plane-blocks-for-acute-and-chronic-post-mastectomy-pain-100626648","NCT07438366","Adding Magnesium Sulphate to Combined Pectointercostal Plane and Erector Spinae Plane Blocks for Acute and Chronic Post-Mastectomy Pain","Efficacy of Adding Magnesium Sulphate to Combined Pectointercostal Plane Block and Erector Spinae Plane Block for Acute and Chronic Post-Mastectomy Pain After Modified Radical Mastectomy. A Controlled Clinical Trial","Inclusion Criteria:\n\n* Female patients aged ≥18 years.\n* American Society of Anesthesiologists (ASA) class I-III.\n* Scheduled for unilateral modified radical mastectomy.\n\nExclusion Criteria:\n\n* Known allergy to local anesthetics or magnesium.\n* Coagulopathy or anticoagulant therapy.\n* Local infection at injection site.\n* Body mass index (BMI) ≥ 40 kg\u002Fm2.\n* Chronic opioid use or chronic pain disorders.\n* Neurological or psychiatric disorders affect pain perception.\n* Severe hepatic or renal impairment.\n* Pregnancy.\n* Lactation.",{"count":115,"type":22},60,[25],"Given the burden of chronic postmastectomy pain and the need for effective, opioid-sparing analgesia, the propose of the randomized controlled trial is to evaluate the safety and efficacy of adding magnesium sulphate to the combination of PIP block and ESPB in patients undergoing modified radical mastectomy for reducing acute and chronic post mastectomy pain",[70],"2026-02-22",{"date":121,"type":47},"2026-02-27",{"date":123,"type":22},"2026-02-15",{"date":125,"type":22},"2027-02-15",{"name":127,"class":54},"South Egypt Cancer Institute"]